1 / 34

Endovaskuläre Therapie von Aortenklappenpathologien

Endovaskuläre Therapie von Aortenklappenpathologien. TAVI Kurt Huber, Wilhelminenspital , Wien. Historical background. 2000 Bonhoeffer et al. – Pulmonary valve 2002 Cribier et al. – Aortic valve 2007 Approval for CoreValve TM and Sapien TM (Europe) 2010 Partner trial

novia
Download Presentation

Endovaskuläre Therapie von Aortenklappenpathologien

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EndovaskuläreTherapie von Aortenklappenpathologien TAVI Kurt Huber, Wilhelminenspital, Wien

  2. Historicalbackground 2000 Bonhoeffer et al. – Pulmonary valve 2002 Cribier et al. – Aortic valve 2007 Approval for CoreValveTM and SapienTM (Europe) 2010 Partner trial 2013 over 50000 cases worldwide

  3. Therapeutic opportunities SAVR: Surgicalaorticvalvereplacement Firstlinetherapy TAVI: in case of high risk or inoperability (EURO Score >20% or STS >10%) (Iung B, et al.; EurHeart J. 2005 Dec;26(24):2714-20.)

  4. Devices MedtronicCoreValveTM Edwards SapienTM

  5. Specifications Medtronic CoreValveTM • 26mm, 29mm, 31mm • 18 French delivery catheter • Self expanding • Nitinol • Porcine pericardium Edwards SapienTM • 23mm, 26mm, 29mm • 18 French delivery catheter • Balloon expandable • Cobalt chromium • Bovine pericardium

  6. Approach Percutaneous:-Transfemoral -Transjugular -Transcarotid Surgical: -Transapical -Transaortal

  7. Requirements TTE/TEE Carotid artery sonography CT-Angiography MMSE/Frailty Score/Quality of Life Heart team assessment

  8. Complications - VARC Procedurefailure MyocardialInfarction Stroke Bleeding Vascular Access sitecomplication Akute kidneyinjury Conductiondisturbances

  9. GARYDeutschesAortenklappenregister GermanAorticValveRegistrY C.W.Hamm,F.W.Mohr,H.Möllmann,D.Holzhey, A.Beckmann,H.-R.Figulla,J.Cremer,K.-H.Kuck,R.Lange, R.Zahn,S.Sack,G.Schuler,T.Walther,F.Beyersdorf, M.Böhm,G.Heusch,A.-K.Funkat,T.Meinertz,T.Neumann, K.Papoutsis,S.Schneider,A.WelzfortheGARY-Executive Board ChristianW.Hamm KerckhoffHeartandThoraxCenterBadNauheimand MedicalClinicI,UniversityofGiessen,Germany

  10. GARY Rationale • Nationwidecompletesurveyofpatientswithaortic valvestenosisundergoinginvasiveprocedures: •  •  •  •  surgical(AVR), catheter-based(TAVI)transfemoral, catheter-based(TAVI)transapical, valvuloplasty. • Toevaluatecatheter-basedproceduresin comparisontosurgicalaorticvalvereplacement. • Developcriteriaforanadequatepatientselectionof besttreatmentmodality.

  11. GARY Design • Prospective,controlled,multicenterregistry. • Allpatientsundergoinganinvasivetherapyfor acquiredaorticvalvediseaseconsecutively included. • Theonlyexclusioncriterion:noinformedconsent. • Follow-up:in-hospital,30days,1,3,5years.

  12. GARY TAVIValveType transvascular transapical Others Others n=1.181 n=2.695

  13. GARY BaselineCharacteristics allp<0.001

  14. GARY BaselineCharacteristics n=6517 n=3458 n=2689 n=1177 100% Patients>75years 44,9% 33,3% 86,3% 84,0% 80% 60% 40% 20% 0% withoutCABG withCABG transvascular transapical SurgicalAVR TAVI

  15. GARY BaselineCharacteristics n=2689 n=1177 n=6517n=3458 Femalegender 70% 60% 58,8% 50% 49,8% 40% 30% 39,0% 28,4% 20% 10% 0% withoutCABG withCABG transvascular transapical SurgicalAVR TAVI

  16. GARY BaselineCharacteristics Heartfailure(NYHAIII/IV) n=2694 86% n=1181 86% n=6523 62% n=3462 69% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% withoutCABG withCABG transvascular transapical SurgicalAVR TAVI

  17. GARY Results–Outcome n=1177 7,7% n=2689 5,1% n=6517n=3458 Mortality(in-hospital) 4,5% 2,1% 9,0% 8,0% 7,0% 6,0% 5,0% 4,0% 3,0% 2,0% 1,0% 0,0% withoutCABG withCABG transvascular transapical SurgicalAVR TAVI

  18. GARY Results–Procedure NewPacemaker n=6517 n=3458 n=2689 n=1177 25% 23,7% 20% 15% 10% 9,9% 4,6% 3,9% 5% 0% withoutCABG withCABG transvascular transapical SurgicalAVR TAVI

  19. GARY Results–EuroScore Euro-Scorein-hospitalmortality SurgicalAVR TAVI 60% withoutCABG withCABG transvascular transapical 50% 40% 30% 20% 10% 0% <10%<20%<30%≥30% <10%<20%<30%≥30% <10%<20%<30%≥30% <10%<20%<30%≥30% observed1,3%3,3%3,8%7,8% expected4,7%13,7%24,3%45,3% 2,6%4,8%8,5%17,7% 5,3%14,0%24,1%45,0% 3,9%3,5%4,7%7,7% 7,3%14,5%24,5%48,4% 3,6%5,5%6,5%13,6% 7,4%14,6%24,2%47,4%

  20. GARY Risk-adjustedIn-HospitalMortality Reference:AVRwithoutCABG TAVI transvascular TAVI transapical TAVI transvascular TAVI transapical <75years ≥75years 0,0 1,0 2,0 3,0 4,0 5,0 6,0 7,0

  21. The Wilhelminenspital TAVI Registry - providing an international comparison Florian Egger, Matthias Freynhofer, Gerhard Unger, Kurt Huber

  22. Aorticstenosis 3. Med Braunwald et al. Textbook of Cardiov. Med 2004

  23. TAVI - Bioprothesis MedtronicCoreValveTM Edwards SapienTM

  24. WSP TAVI Registry - Patients • *Characteristics: • -Transvalvular gradient > 40mmHg or • -Aortic valve area < 1cm2 • Operability assessed by heart team

  25. WSP TAVI Registry - Outcome NYHA classbefore and after TAVI Mean/peaktransvalvulargradient

  26. WSP TAVI Registry - Outcome 1 yearsurvival (Kaplan Meier) Endpoints (30 Days)

  27. International comparison Clinical Trials: PARTNER B (179 Pat., transfemoral, RCT, Edwards) Registries: SOURCE (463 Pat., transfemoral/-apical, Edwards) FRANCE 2 (2293 Pat., transfemoral/-apical, Edwards/Medtronic) Limitations: -Self reporting (Registries) -Selected patient population (Clinical trials) -incomparable results due to inconsistent endpoint reporting (VARC)

  28. International comparison - Patients

  29. International Comparison - Outcome Himbert D, et al.; Am J Cardiol. 2009 Jul. 21; 54(4):303-11 Gurvitch R, et al.; CatheterCardiovascInterv 2011;78:977–984.

  30. International Comparison - Outcome

  31. Conclusion & Outlook HEART TEAM Approach Gefäßchirurgie-WSP, Anästhesie (WSP), Herzchirurgie + Kardiotechniker (Hietzing) Optimal equipment (Heart-Lung-Machine) Higher caseload desirable to guarantee safety and high quality Pacemaker sub-study

  32. CoreValveInnovation FocusedEffortson: •Expansionofpatientaccess •Furtherimprovementofeaseofuse •Continuetoadvancepatientandproceduraloutcome Anti- Mineralization TissueTreatment *Delivery System Improvements Alternative Access Technology 16FR 18FR Profile Reduction *GreaterAnnulus Coverage

  33. NewTAVIvalvesarecomingtothe marketinafewyear’stime Today Tomorrow BostonSci. Lotus™ NextGen. Medtronic CoreValve HLT Edwards SapienXT SaintJude Portico™ DirectFlow Medtronic CoreValve Medtronic Engager Edwards Sapien JenaValve Symetis ACCURATE Edwards SapienXT

  34. Thankyouforyourattention !

More Related